Provide dose justification and information on global standards, the CDSCO panel instructs Synokem regarding Sacubitril and valsartan FDC.

Published Date: 28 Aug 2023

In response to the clinical trial protocol for the medication mix of sacubitril and valsartan presented by the pharmaceutical company Synokem, the.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot